Cabazitaxel was approved for patients with metastatic castration-resistant prostate cancer progressing after docetaxel [1] . We have reported four cases of cabazitaxel-induced hematuria and cystitis (Table 1) . Each of the patients had hematuria during exposure to the drug. Cystoscopy showed evidence of inflammation of the bladder, and biopsies of two patients showed hemorrhagic cystitis, with no evidence of tumor. All patients had a past history of pelvic radiation. 'It is likely that these 4 cases of hemorrhagic cystitis in men previously treated with pelvic radiation therapy were due to a radiation recall syndrome induced by cabazitaxel'. Urinary infection was eliminated in all patients. Discontinuation of cabazitaxel led to cessation of hematuria in all cases, as described in previously reported radiation recall cases [2] . Also, all patients had cystoscopy with evidence of bladder inflammation limited to the previous irradiation fields, with biopsies from two of them showing lesions compatible with radiation cystitis. Clinically, neither skin reaction nor symptoms related to a radiation proctitis was recorded at the time of urinary symptoms.
Further evidence for a radiation recall phenomenon is provided by the difference in number of cases of hemorrhagic cystitis or hematuria following treatment with cabazitaxel, depending on whether the patients had previous pelvic radiotherapy or not. There were no reports of hematuria in the most recently reported phase I trial where participants had not received pelvic radiation, [3] , 3% of any grade hematuria in a phase II in patients with breast cancer [4], compared with 17% hematuria of any grade and 2% of grade 3 in the cabazitaxel arm in the TROPIC trial [1] .
The metabolism of cabazitaxel does not provide an explanation for the occurrence of hemorrhagic cystitis. Cabazitaxel is mainly metabolized by the liver (CYP3A4/5: 80%-90%) and excreted in the feces, while renal excretion of cabazitaxel and its metabolites account for about 3.7% of the dose (2.3% as unchanged drug in urine).
The timing of hematuria was during the period of aplasia induced by cabazitaxel but no hematuria has been described during aplasia induced by other cytotoxic drugs, e.g. docetaxel in the same patients. During hematuria, no patients had abnormal coagulation or grade 3-4 thrombopenia; however, one patient had aspirin 75 mg/day. There was no variation of hepatic function or concomitant statin treatment which could be associated with radiation recall syndrome [5] . These four events occurred during 149 courses of cabazitaxel in 28 patients given treatment of mCRPC.
Our observations may guide management of patients with a past history of pelvic radiation and suggest the importance of urologic investigation before concluding that hematuria represents progression of prostate cancer. Incidence of bowel perforation in gastrointestinal lymphomas by location and histology
We recently reported a 9% incidence of bowel perforation in our cohort of 1062 patients with biopsy-proven GI involvement with lymphoma [1] . Among the 100 perforation events, the small bowel was the most common site of perforation and diffuse large B-cell lymphoma (DLBCL) was the most common histology. The risk of perforation seems to vary by both the site of involvement as well as the type of lymphoma. Herein, we report additional data from the same cohort of patients regarding site-specific incidence of perforation, stratified by lymphoma histology (Table 1) . Among the 1062 GI lymphomas in our series, the stomach was the most frequent site of involvement (44%), followed by the colon/rectum (25%), small bowel (24%) and duodenum (7%). The esophagus was the least frequently involved (<1%). Overall, DLBCL was the most frequent histology (39%) and was associated with the highest frequency of perforations (13.2%), whereas mucosa-associated lymphoid tissue (MALT) lymphoma, the next most frequent histology (21%), was associated with a much lower risk of perforation (1.8%). In general, low-grade lymphomas perforated less frequently than their high-grade counterparts, irrespective of the site of involvement. For example the frequency of perforation was 6% with gastric DLBCL compared with 0.6% with gastric MALT, and 13.2% with colorectal DLBCL compared with 0% with colorectal MALT. However, the site of involvement is also important in determining the risk of perforation, and may be related to the thickness of the involved bowel wall. MALT lymphomas in the small bowel had a higher risk of perforation 
